Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Rita De Santis directs the Department of Biotech Products at Sigma Tau SpA, Italy. Rita’s group previously published that injected oxidised Avidin, called AvidinOX, exhibits the distinctive property to form Schiff’s bases with tissue proteins thus constituting a stable receptor for biotinylated therapeutics. AvidinOX is currently under clinical investigation in Europe and USA to target radioactive biotin to inoperable tumor masses. Previous data also proved that AvidinOX can be employed for targeting biotinylated cells or biotinylated antibodies. Interestingly, a strong anti-tumor activity of AvidinOX-anchored biotinylated Cetuximab (bCet) was observed, against EGFR+ tumor cells. The talk will illustrate how to exploit this unexpected result for new cancer therapies.
